Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct;11(8):717-719.
doi: 10.1002/ueg2.12436. Epub 2023 Jul 3.

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?

Ferdinando D'Amico  1   2 , Laurent Peyrin-Biroulet  3   4   5   6   7   8 , Silvio Danese  1
Affiliations
Editorial

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?

Ferdinando D'Amico et al. United European Gastroenterol J. 2023 Oct.
No abstract available

Keywords: IBD; gastroenterology; inflammation; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

F. D’Amico has served as a speaker for Sandoz, Janssen, Galapagos, and Omega Pharma; he also served as an advisory board member for Galapagos, Abbvie and Nestlè. L. Peyrin‐Biroulet received fees from AbbVie, Adacyte, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC‐Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Nordic Pharma, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sanofi, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax, Samsung, Ventyx, Roivant, Vectivbio. S. Danese has served as a speaker, consultant, and advisory board member for Schering‐Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor.

References

    1. Peyrin‐Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat‐to‐target. Am J Gastroenterol. 2015;110(9):1324–1338. 10.1038/ajg.2015.233 - DOI - PubMed
    1. Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE‐II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat‐to‐target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. 10.1053/j.gastro.2020.12.031 - DOI - PubMed
    1. Danese S, Roda G, Peyrin‐Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol. 2020;17:1–2. 10.1038/s41575-019-0211-1 - DOI - PubMed
    1. D’Amico F, Fiorino G, Solitano V, Massarini E, Guillo L, Allocca M, et al. Ulcerative colitis: impact of early disease clearance on long‐term outcomes – a multicenter cohort study. Uni. Eur Gastroenterol J. 2022;10(7):775–782. 10.1002/ueg2.12288 - DOI - PMC - PubMed
    1. Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate‐to‐severe plaque psoriasis (IMMvent): a randomised, double‐blind, active‐comparator‐controlled phase 3 trial. Lancet. 2019;394(10198):576–586. 10.1016/s0140-6736(19)30952-3 - DOI - PubMed

Publication types

MeSH terms